GlassScriptPhysician profile
Holly Harris
NPI 1740342161
$2,510.05
in general payments reported to CMS, 2019-2025
27 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $408 · 2021: $758 · 2022: $154 · 2023: $62.87 · 2024: $56.49 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $647.46 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $443.10 | 2019-2025 | Zepbound |
| Abbvie INC. | $292.16 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $129.71 | 2021 | |
| Exact Sciences Corporation | $124.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $118.73 | 2020-2025 | Krystexxa, Lumakras |
| Ibsa Pharma INC. | $88.28 | 2022 | |
| Pfizer INC. | $84.84 | 2021 | |
| Viiv Healthcare Company | $70.13 | 2025 | Apretude |
| Allergan, INC. | $48.02 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $48.00 | 2020 | |
| Boston Scientific Corporation | $46.89 | 2025 | Bodyguardian |
| Melinta Therapeutics, LLC | $45.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $39.01 | 2019-2025 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $35.06 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $34.55 | 2019 | |
| Abiomed | $31.51 | 2024 | Impella |
| Currax Pharmaceuticals LLC | $28.35 | 2019-2020 | |
| Hologic Sales and Service, LLC | $25.77 | 2019 | |
| Astellas Pharma US INC | $20.19 | 2025 | Veozah |
| Kerecis Limited | $18.17 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.74 | 2019 | |
| Glaxosmithkline, LLC. | $16.55 | 2021 | |
| Zimmer Biomet Holdings, INC. | $16.43 | 2019 | |
| Merck Sharp & Dohme LLC | $15.14 | 2019 | |
| Amarin Pharma, INC. | $13.07 | 2019 | |
| Tactile Systems Technology INC | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.